Protective effect of hepatitis b vaccine combined with two-dose hepatitis b immunoglobulin on infants born to hbsag-positive mothers

PLoS ONE

Volumn 6, Issue 10, 2011, Pages

  Zou, Huaibin ^a   Chen, Yu ^a   Duan, Zhongping ^a   Zhang, Hua ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS C VACCINE; VIRUS DNA; HEPATITIS B HYPERIMMUNE GLOBULIN; HEPATITIS B VACCINE; IMMUNOGLOBULIN; PROTECTIVE AGENT;

ANTIBODY BLOOD LEVEL; ARTICLE; BIRTH WEIGHT; CHINA; CONTROLLED STUDY; FEMALE; GENDER; GESTATIONAL AGE; HEPATITIS C; HUMAN; IMMUNE RESPONSE; INFANT; MAJOR CLINICAL STUDY; MALE; MOTHER; RETROSPECTIVE STUDY; TREATMENT FAILURE; DOSE RESPONSE; DRUG COMBINATION; GENETICS; HEPATITIS B; IMMUNIZATION; IMMUNOLOGY;

HEPATITIS B VIRUS;

DNA, VIRAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION; IMMUNOGLOBULINS; INFANT; MALE; MOTHERS; PROTECTIVE AGENTS; TREATMENT FAILURE;

EID: 80055063176     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0026748     Document Type: Article

References (41)

1. Lee WM, (1997) Hepatitis B virus infection. N Engl J Med 337: 1733-1745.
2. Lai CL, Ratziu V, Yuen MF, (2003) Viral hepatitis B. Lancet 362: 2089-2094.
3. Lok AS, McMahon BJ, (2007) Chronic hepatitis B. Hepatology 45: 507-539.
4. Ni YH, Huang LM, Chang MH, Yen CJ, Lu CY, et al. (2007) Two decades of universal hepatitis B vaccination in taiwan: impact and implication for future strategies. Gastroenterology 132: 1287-1293.
5. Weinbaum CM, Williams I, Mast EE, Wang SA, Finelli L, et al. (2008) Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR 57: 1-20.
6. WHO publications (2010) Hepatitis B vaccines: WHO position paper- recommendations. Vaccine 28: 589-590.
7. Lee CF, Gong Y, Brok J, Boxall EH, Gluud C, (2006) Effect of hepatitis B immunisation in newborn infants of mothers positive for hepatitis B surface antigen: systematic review and meta-analysis. BMJ 332: 328-336.
8. Roukens AH, Vossen AC, Boland GJ, Verduyn W, van Dissel JT, et al. (2010) Intradermal hepatitis B vaccination in non-responders after topical application of imiquimod (Aldara®). Vaccine 28: 4288-4293.
9. Zhu QR, Yu GJ, Yu H, Lu Q, Gu X, et al. (2003) A randomized control trial on interruption of HBV transmission in uterus. Chin Med J(Engl) 116: 685-687.
10. Song YM, Sung J, Yang S, Choe YH, Chang YS, et al. (2007) Factors associated with immunoprophylaxis failure against vertical transmission of hepatitis B virus. Eur J Pediatr 166: 813-818.
11. Wong VC, Ip HM, Reesink HW, Lelie PN, Lelie PN, et al. (1984) Prevention of the HBsAg carrier state in newborn infants of mothers who are chronic carriers of HBsAg and HBeAg by administration of hepatitis-B vaccine and hepatitis-B immunoglobulin. Double-blind randomised placebo-controlled study. Lancet 1: 921-926.
12. Beasley RP, Hwang LY, Lee GC, Lan CC, Roan CH, et al. (1983) Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine. Lancet 2 (8359): 1099-1102.
13. Centers for Disease Control and Prevention (CDC) (2011) Assessing completeness of perinatal hepatitis B virus infection reporting through comparison of immunization program and surveillance data-United States. MMWR Morb Mortal Wkly Rep 60: 410-413.
14. Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association (2005) Chinese National Viral Hepatitis Prevention Conference: Viral Hepatitis Control Programme. Zhonghua Ganzangbing Zazhi 13: 881-991.
15. Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association (2011) The guideline of prevention and treatment for chronic hepatitis B. Zhonghua Ganzangbing Zazhi 1: 11-23.
16. Beasley RP, Hwang LY, Stevens CE, Lin CC, Hsieh FJ, et al. (1983) Efficacy of hepatitis B immune globulin for prevention of perinatal transmission of the hepatitis B virus carrier state: final report of a randomized double-blind, placebo-controlled trial. Hepatology 3: 135-141.
17. Grosheide PM, del Canho R, Voogd M, Heijtink RA, Schalm SW, (1994) Anti-HBs levels in infants of hepatitis B carrier mothers after delayed active immunization with recombinant vaccine concomitant with DTP-polio vaccine: is there need for a second dose of HBIg? Dutch Study Group on Prevention of Neonatal Hepatitis B. Vaccine 12: 1059-1063.
18. Burk RD, Hwang LY, Ho GY, Shafritz DA, Beasley RP, (1994) Outcome of perinatal hepatitis B virus exposure is dependent on maternal virus load. J Infect Dis 170: 1418-1423.
19. del Canho R, Grosheide PM, Mazel JA, Heijtink RA, Hop WC, et al. (1997) Ten-year neonatal hepatitis B vaccination program, The Netherlands, 1982-1992: protective efficacy and long-term immunogenicity. Vaccine 15: 1624-1630.
20. Burk RD, Hwang LY, Ho GY, Shafritz DA, Beasley RP, (1994) Outcome of perinatal hepatitis B virus exposure is dependent on maternal virus load. J Infect Dis 170: 1418-1423.
21. Wiseman E, Fraser MA, Holden S, Glass A, Kidson BL, et al. (2009) Perinatal transmission of hepatitis B virus: an Australian experience. Med J Aust 190: 489-492.
22. Craven DE, Awdeh ZL, Kunches LM, Yunis EJ, Dienstag JL, et al. (1986) Nonresponsiveness to hepatitis B vaccine in health care workers. Results of revaccination and genetic typings. Ann Intern Med 105: 356-360.
23. Alper CA, (1995) The human immune response to heaptitis B surface antigen. Exp Clin immunogenet 12: 171-181.
24. Hollinger FB, (1989) Factors influencing the immune response to hepatitis B vaccine, booster dose guidelines, and vaccine protocol recommendations. Am J Med 3A: S36S-40.
25. Wood RC, MacDonald KL, White KE, Hedberg CW, Hanson M, et al. (1993) Risk factors for lack of detectable antibody following hepatitis B vaccination of Minnesota health care workers. JAMA 270: 2935-2939.
26. Yen YH, Chen CH, Wang JH, Lee CM, Changchien CS, et al. (2005) Study of hepatitis B (HB) vaccine non-responsiveness among health care workers from an endemic area (Taiwan). Liver Int 25: 1162-1168.
27. Milich DR, Leroux-Roels GG, (2003) Immunogenetics of the response to HBsAg vaccination. Autoimmun Rev 2: 248-257.
28. Singh R, Kaul R, Kaul A, Khan K, (2007) A comparative review of HLA associations with hepatitis B and C viral infections across global populations. World J Gastroenterol 13: 1770-1787.
29. Liu P, Xu H, Wang X, Li H, Zhuang G, et al. (2000) Field epidemiological and experimental study on relationship between genetic factor and nonresponse or hyporesponse to hepatitis B vaccine. Chin Med J (Engl) 113: 547-550.
30. Hsu HY, Chang MH, Ho HN, Hsieh RP, Lee SD, et al. (1993) Association of HLA-DR14-DR-52 with low responsiveness to hepatitis B vaccine in Chinese residents in Taiwan. Vaccine 11: 1437-1440.
31. Roberton DM, Marshall H, Dinan L, Boros C, Gold M, (2004) Developmental immunology and vaccines: immune responses to vaccines in premature infants. Expert Rev Vaccines 3: 343-347.
32. D'Angio CT, (2007) Active immunization of premature and low birth-weight infants: a review of immunogenicity, efficacy, and tolerability. Pediatr Drugs 9: 17-32.
33. Lee C, Gong Y, Brok J, Boxall EH, Gluud C, (2006) Hepatitis B immunisation for newborn infants of hepatitis B surface antigen-positive mothers. Cochrane Database Syst Rev 2: CD004790.
34. Lu CY, Ni YH, Chiang BL, Chen PJ, Chang MH, et al. (2008) Humoral and cellular immune responses to a hepatitis B vaccine booster 15-18 years after neonatal immunization. J Infect Dis 197: 1419-1426.
35. Jan CF, Huang KC, Chien YC, Greydanus DE, Davies HD, et al. (2010) Determination of immune memory to hepatitis B vaccination through early booster response in college students. Hepatology 51: 1547-1554.
36. Junqueira AL, Tavares VR, Martins RM, Frauzino KV, da Costa e Silva AM, et al. (2010) Safety and immunogenicity of hepatitis B vaccine administered into ventrogluteal vs. anterolateral thigh sites in infants: a randomised controlled trial. Int J Nurs Stud 47: 1074-1079.
37. Agladioglu S, Beyazova U, Camurdan AD, Sahin F, Atak A, (2010) Immunogenicity of recombinant hepatitis B vaccine: comparison of two different vaccination schedules. Infection 38: 269-273.
38. Niu MT, Davis DM, Ellenberg S, (1996) Recombinant hepatitis B vaccination of neonates and infants: emerging safety data from the vaccine adverse event reporting system. Pediatr Infect Dis J 15: 771-776.
39. Bohlke K, Davis RL, Marcy SM, Braun MM, DeStefano F, et al. (2003) Risk of anaphylaxis after vaccination of children and adolescents. Pediatrics 112: 815-820.
40. Kojouharova M, Teoharov P, Bahtchevanova T, Maeva I, Eginlian A, et al. (2001) Safety and immunogenicity of a yeast-derived recombinant hepatitis B vaccine in Bulgarian newborns. Infection 29: 342-344.
41. Lewis E, Shinefield HR, Woodruff BA, Black SB, Destefano F, Vaccine Safety Datalink Workgroup (2001) Safety of neonatal hepatitis B vaccine administration. Pediatr Infect Dis J 2001;20: 1049-1054.